JP2011519847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011519847A5 JP2011519847A5 JP2011506772A JP2011506772A JP2011519847A5 JP 2011519847 A5 JP2011519847 A5 JP 2011519847A5 JP 2011506772 A JP2011506772 A JP 2011506772A JP 2011506772 A JP2011506772 A JP 2011506772A JP 2011519847 A5 JP2011519847 A5 JP 2011519847A5
- Authority
- JP
- Japan
- Prior art keywords
- support
- product
- antigen
- cell
- immunostimulant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 36
- 239000000427 antigen Substances 0.000 claims 27
- 102000036639 antigens Human genes 0.000 claims 27
- 108091007433 antigens Proteins 0.000 claims 27
- 230000003308 immunostimulating effect Effects 0.000 claims 20
- 210000003719 b-lymphocyte Anatomy 0.000 claims 16
- 229960001438 immunostimulant agent Drugs 0.000 claims 16
- 239000003022 immunostimulating agent Substances 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 238000004519 manufacturing process Methods 0.000 claims 9
- 230000001404 mediated effect Effects 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- 238000002360 preparation method Methods 0.000 claims 5
- 108010001441 Phosphopeptides Proteins 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000000556 agonist Substances 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000003844 B-cell-activation Effects 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 150000002632 lipids Chemical group 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000000638 stimulation Effects 0.000 claims 2
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical group CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims 1
- HOMYIYLRRDTKAA-UHFFFAOYSA-N 2-hydroxy-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]hexadecanamide Chemical compound CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=CCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O HOMYIYLRRDTKAA-UHFFFAOYSA-N 0.000 claims 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 claims 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 claims 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 1
- 229930186217 Glycolipid Natural products 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 230000036755 cellular response Effects 0.000 claims 1
- 229940106189 ceramide Drugs 0.000 claims 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 1
- 150000003019 phosphosphingolipids Chemical group 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4981408P | 2008-05-02 | 2008-05-02 | |
| US61/049,814 | 2008-05-02 | ||
| PCT/GB2009/001111 WO2009133378A2 (en) | 2008-05-02 | 2009-05-05 | Products and methods for stimulating an immune response |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014160906A Division JP2015028023A (ja) | 2008-05-02 | 2014-08-07 | 免疫応答を刺激するための作製物および方法 |
| JP2014160907A Division JP5853068B2 (ja) | 2008-05-02 | 2014-08-07 | 免疫応答を刺激するための作製物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011519847A JP2011519847A (ja) | 2011-07-14 |
| JP2011519847A5 true JP2011519847A5 (enExample) | 2012-06-07 |
| JP5721620B2 JP5721620B2 (ja) | 2015-05-20 |
Family
ID=40888253
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011506772A Expired - Fee Related JP5721620B2 (ja) | 2008-05-02 | 2009-05-05 | 免疫応答を刺激するための作製物および方法 |
| JP2014160906A Pending JP2015028023A (ja) | 2008-05-02 | 2014-08-07 | 免疫応答を刺激するための作製物および方法 |
| JP2014160907A Expired - Fee Related JP5853068B2 (ja) | 2008-05-02 | 2014-08-07 | 免疫応答を刺激するための作製物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014160906A Pending JP2015028023A (ja) | 2008-05-02 | 2014-08-07 | 免疫応答を刺激するための作製物および方法 |
| JP2014160907A Expired - Fee Related JP5853068B2 (ja) | 2008-05-02 | 2014-08-07 | 免疫応答を刺激するための作製物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20110280930A1 (enExample) |
| EP (3) | EP2288381A2 (enExample) |
| JP (3) | JP5721620B2 (enExample) |
| CN (1) | CN102170903B (enExample) |
| AU (1) | AU2009241645B2 (enExample) |
| CA (1) | CA2723226A1 (enExample) |
| ES (1) | ES2570973T3 (enExample) |
| WO (1) | WO2009133378A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2288381A2 (en) * | 2008-05-02 | 2011-03-02 | Cancer Research Technology Limited | Products and methods for stimulating an immune response |
| WO2012088414A1 (en) * | 2010-12-23 | 2012-06-28 | Ludwig Institute For Cancer Research Ltd. | Liposomal formulation of nonglycosidic ceramides and uses thereof |
| US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
| CN107115314B (zh) | 2011-06-02 | 2022-04-29 | 加利福尼亚大学董事会 | 膜包封的纳米颗粒及使用方法 |
| WO2014133106A1 (ja) * | 2013-02-27 | 2014-09-04 | 独立行政法人理化学研究所 | アレルギー疾患治療薬 |
| GB2514591A (en) | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
| CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| WO2015021390A2 (en) | 2013-08-08 | 2015-02-12 | The Regents Of The University Of California | Nanoparticles leverage biological membranes to target pathogens for disease treatment and diagnosis |
| WO2015084677A1 (en) * | 2013-12-02 | 2015-06-11 | Arytha Biosciences, Llc | Toxoid preparation and uses thereof |
| WO2015143295A2 (en) | 2014-03-20 | 2015-09-24 | The Regents Of The University Of California | Hydrogel compositions containing toxin-absorbing or binding nanoparticles and uses thereof |
| CN107073090A (zh) | 2014-04-30 | 2017-08-18 | 哈佛学院董事会 | 结合的疫苗装置和杀死癌细胞的方法 |
| AU2015269412B2 (en) * | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| US11150242B2 (en) * | 2015-04-10 | 2021-10-19 | President And Fellows Of Harvard College | Immune cell trapping devices and methods for making and using the same |
| US10610493B2 (en) | 2015-04-29 | 2020-04-07 | The Regents Of The University Of California | Detoxification using nanoparticles |
| AU2016277471A1 (en) * | 2015-06-10 | 2018-01-04 | Astrid TSCHIERSCH-PFREUNDSCHUH | Means and methods for treatment of B-cell malignancies |
| WO2017136837A1 (en) | 2016-02-06 | 2017-08-10 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
| NL2017204B1 (en) * | 2016-06-08 | 2017-12-18 | Kei International Ltd | Solid substrate comprising antigens immobilised thereto, biosensor comprising said solid substrate and method for detecting the presence of mycobacterial material in a sample |
| WO2017211314A1 (en) | 2016-06-08 | 2017-12-14 | Kei International Limited | Method for detecting presence of mycobacterial material in sample using immobilised mannosyl phosphoketide antigen |
| AU2017295704B2 (en) | 2016-07-13 | 2023-07-13 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
| CN110418651A (zh) | 2016-08-02 | 2019-11-05 | 哈佛学院院长等 | 用于调节免疫应答的生物材料 |
| CN110114468A (zh) * | 2016-08-17 | 2019-08-09 | 奥比思健康解决方案有限责任公司 | 靶向肿瘤的珠载体及其使用方法 |
| AU2018316253A1 (en) * | 2017-08-10 | 2020-01-16 | Dana-Farber Cancer Institute, Inc. | LMP1-expressing cells and methods of use thereof |
| NL2021443B1 (en) | 2018-08-08 | 2020-02-20 | Kei International Ltd | Synthetic antigens for tuberculosis detection |
| WO2020061129A1 (en) | 2018-09-19 | 2020-03-26 | President And Fellows Of Harvard College | Compositions and methods for labeling and modulation of cells in vitro and in vivo |
| EP3650466A1 (en) * | 2018-11-12 | 2020-05-13 | Consejo Superior De Investigaciones Científicas | In vitro production of high affinity monoclonal antibodies |
| CN111229023B (zh) * | 2018-11-29 | 2022-01-28 | 内蒙古东盛硅藻土科技创新产业园有限公司 | 一种化学降解添加剂 |
| JP2022514568A (ja) | 2018-12-17 | 2022-02-14 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 免疫系のモジュレーションのための生物工学的スキャフォールドおよびその使用 |
| JP2022549270A (ja) | 2019-09-23 | 2022-11-24 | プレジデント アンド フェローズ オブ ハーバード カレッジ | バイオマテリアルベースの無抗原ワクチンおよびその使用 |
| CN112300987B (zh) * | 2020-10-16 | 2022-04-29 | 中国农业大学 | 单个浆细胞的筛选方法及其在小分子单克隆抗体制备中的应用 |
| CN116286631A (zh) * | 2023-02-15 | 2023-06-23 | 上海长征医院 | 一种利用CD79b单克隆抗体诱导构建B细胞免疫无能模型及其构建方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK590288D0 (da) | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
| ES2092560T5 (es) | 1989-12-22 | 2004-09-16 | Mikrogen Molekularbiologische Entwicklungs-Gmbh | Proteinas inmunologicamente activas de borrelia burgdorferi, estuches de ensayo relacionados y vacuna. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| FI933580L (fi) | 1991-02-15 | 1993-10-13 | Uab Research Foundation | Strukturgen av pneumokockprotein |
| US6113914A (en) | 1991-08-15 | 2000-09-05 | Smithkline Beecham Biologicals (S.A.) | Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
| ES2194010T3 (es) | 1991-10-22 | 2003-11-16 | Symbicom Ab | Mejoras en el diagnostico y profilaxis de la borrelia burgdorferi. |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US6004763A (en) * | 1992-09-11 | 1999-12-21 | Institut Pasteur | Antigen-carrying microparticles and their use in the induction of humoral or cellular responses |
| FR2695563B1 (fr) * | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
| CA2196311A1 (en) | 1994-08-19 | 1996-02-29 | David H. Sachs | Genetically engineered swine cells |
| AU2002327338A1 (en) | 2001-07-25 | 2003-02-17 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| DE10164309A1 (de) * | 2001-12-28 | 2003-07-10 | Fraunhofer Ges Forschung | Verbesserte strukturiert-funktionale Bindematrices für Biomoleküle |
| WO2004016283A2 (en) * | 2002-08-14 | 2004-02-26 | Avidis Sa | Heteropolymeric compound comprising a scaffold, an adjuvant and an antigen, and its use |
| WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| JP2008504216A (ja) * | 2003-12-02 | 2008-02-14 | サイトイミューン サイエンシズ インコーポレイテッド | モノクローナル抗体の生成のための方法および組成物 |
| EP1767216B1 (en) | 2004-06-11 | 2012-07-11 | Riken | Drug having regulatory cell ligand contained in liposome |
| AU2005259685B2 (en) | 2004-07-07 | 2010-04-08 | Statens Serum Institut | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids |
| ES2625905T3 (es) * | 2004-10-01 | 2017-07-20 | Midatech Ltd. | Nanopartículas que comprenden antígenos y adyuvantes capaces de estimular linfocitos T cooperadores |
| DE602006008278D1 (de) * | 2005-03-02 | 2009-09-17 | Pharmazeutische zusammensetzung | |
| BRPI0617687A2 (pt) | 2005-10-25 | 2011-08-02 | Ludwig Inst Cancer Res | composto, método para proteger um indivìduo mamìfero contra, ou tratar, um vìrus, infecção microbiana, parasita, uma doença auto-imune, cáncer, alergia ou asma, e, composição farmacêutica |
| US20070231344A1 (en) | 2005-10-28 | 2007-10-04 | The Brigham And Women's Hospital, Inc. | Conjugate vaccines for non-proteinaceous antigens |
| WO2007051004A2 (en) | 2005-10-28 | 2007-05-03 | The Brigham And Women's Hospital, Inc. | Conjugate vaccines for non-proteinaceous antigens |
| EP2288381A2 (en) * | 2008-05-02 | 2011-03-02 | Cancer Research Technology Limited | Products and methods for stimulating an immune response |
| JP5782775B2 (ja) | 2011-03-29 | 2015-09-24 | ソニー株式会社 | 情報表示装置および情報表示方法、並びにプログラム |
-
2009
- 2009-05-05 EP EP09738408A patent/EP2288381A2/en not_active Withdrawn
- 2009-05-05 EP EP13189438.8A patent/EP2711020B1/en not_active Not-in-force
- 2009-05-05 AU AU2009241645A patent/AU2009241645B2/en not_active Ceased
- 2009-05-05 ES ES13189439T patent/ES2570973T3/es active Active
- 2009-05-05 CA CA2723226A patent/CA2723226A1/en not_active Abandoned
- 2009-05-05 WO PCT/GB2009/001111 patent/WO2009133378A2/en not_active Ceased
- 2009-05-05 EP EP13189439.6A patent/EP2711021B1/en not_active Not-in-force
- 2009-05-05 JP JP2011506772A patent/JP5721620B2/ja not_active Expired - Fee Related
- 2009-05-05 CN CN200980125581.9A patent/CN102170903B/zh not_active Expired - Fee Related
- 2009-05-05 US US12/736,706 patent/US20110280930A1/en not_active Abandoned
-
2014
- 2014-08-07 JP JP2014160906A patent/JP2015028023A/ja active Pending
- 2014-08-07 JP JP2014160907A patent/JP5853068B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dykman | Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases | |
| Demento et al. | Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines | |
| JP5097400B2 (ja) | 複合ワクチン | |
| Kaurav et al. | Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage | |
| Luzuriaga et al. | Biomaterials and nanomaterials for sustained release vaccine delivery | |
| JP5198712B2 (ja) | 免疫原性微粒子を含む組成物 | |
| CN102293743B (zh) | 一种脂质微球组合物 | |
| JP2012522802A (ja) | ワクチン組成物及びその使用方法 | |
| JP2007504237A5 (enExample) | ||
| CA2616344A1 (en) | A method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response | |
| Taki et al. | Small wonders—the use of nanoparticles for delivering antigen | |
| CN103052402B (zh) | 免疫原性组合物 | |
| Gao et al. | Nanovaccines for advancing long-lasting immunity against infectious diseases | |
| Ravi et al. | Biomaterials, biological molecules, and polymers in developing vaccines | |
| Liu et al. | Precision nanovaccines for potent vaccination | |
| Teng et al. | Bi-functional gold nanocages enhance specific immunological responses of foot-and-mouth disease virus-like particles vaccine as a carrier and adjuvant | |
| Wan et al. | Pathogen‐Mimicking Nanoparticles Based on Rigid Nanomaterials as an Efficient Subunit Vaccine Delivery System for Intranasal Immunization | |
| Soni et al. | The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems | |
| Scheiblhofer et al. | Potential of nanoparticles for allergen-specific immunotherapy–use of silica nanoparticles as vaccination platform | |
| CA2801585C (en) | Peptide particle formulation | |
| Yang et al. | Strategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection | |
| Lin et al. | Polyphosphazene: A new adjuvant platform for cocaine vaccine development | |
| Jahan et al. | Potentiating antigen specific immune response by targeted delivery of the PLGA-based model cancer vaccine | |
| You et al. | Generation of T cell responses targeting the reactive metabolite of halothane in mice | |
| Tohumeken et al. | A modular antigen presenting peptide/oligonucleotide nanostructure platform for inducing potent immune response |